Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh(BR:REGN34)
R$92.51+0.78 (+0.85%)
BR:REGN34
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh similar stocks
R$92.51
At close:+0.78 (+0.85%)
Compare Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh (REGN34) vs. Competitors
Comparison Results
| Name | Price | Market Cap | P/E Ratio | Yearly Gain | Analyst Consensus | Analyst Price Target | Compare | Top Analysts' Price Target | Smart Score | Follow |
|---|---|---|---|---|---|---|---|---|---|---|
| BR:REGN34Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh | BRL 92.51 | BRL 575.34B | 23535.90 | 38.49% | ― | Unlock the BR:REGN34 analyst price target with TipRanks Premium | BR:REGN34 | Unlock the BR:REGN34 top-analyst price target with TipRanks Premium | ||
| BR:A1RG34arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR | BRL 220.00 | BRL 346.61B | ― | 15.79% | ― | Unlock the BR:A1RG34 analyst price target with TipRanks Premium | BR:REGN34 vs BR:A1RG34 | Unlock the BR:A1RG34 top-analyst price target with TipRanks Premium | ||
| BR:TAKP34Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR | BRL 125.64 | BRL 404.68B | 179485.71 | 71.59% | ― | Unlock the BR:TAKP34 analyst price target with TipRanks Premium | BR:REGN34 vs BR:TAKP34 | Unlock the BR:TAKP34 top-analyst price target with TipRanks Premium |
Performance Comparison
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BR:REGN34 | Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh | 92.51 | 29.47 | 46.75% | |
| BR:A1RG34 | arGEN-X SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR | 220.00 | 23.80 | 12.13% | |
| BR:TAKP34 | Takeda Pharmaceutical Co. Ltd. Unsponsored Brazilian Depository Receipt Repr 1 ADR | 125.64 | 54.42 | 76.42% |
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts

